Harvard Bioscience Inc (NASDAQ: HBIO) will announce its financial results for the second quarter ended June 30, 2026, before the market opens on August 11, 2026. The life sciences technology developer will host a conference call at 8:00 AM Eastern Time to discuss the quarterly performance and business outlook. This announcement provides investors with a specific timeline for accessing the company's latest operational and financial data.

The conference call offers analysts and shareholders an opportunity to engage directly with management regarding the quarter's outcomes. Participants interested in joining the call must register through the provided link to receive dial-in numbers and a unique PIN. For those preferring audio-only access, a webcast will be available via the company's investor relations website. These logistical details ensure broad accessibility for stakeholders monitoring the firm's progress.

Financial Reporting Details

All financial information presented during the call, including the official earnings release and related slide presentations, will be posted on the Investor Relations section of Harvard Bioscience’s website. This centralized repository allows for immediate access to detailed metrics following the live discussion. The company emphasizes transparency by making these documents available simultaneously with the public announcement.

About Harvard Bioscience

Harvard Bioscience Inc is a leading developer, manufacturer, and seller of technologies, products, and services that enable fundamental advances in life science applications. Its portfolio supports research, pharmaceutical and therapy discovery, bio-production, and preclinical testing. The company serves a diverse customer base ranging from renowned academic institutions and government laboratories to leading pharmaceutical, biotechnology, and contract research organizations.

With operations in the United States, Europe, and China, Harvard Bioscience sells through a combination of direct and distribution channels globally. Mark Frost, Chief Financial Officer, serves as the primary contact for investor inquiries regarding these financial disclosures.